Sanofi S.A. Revenue & Financials

Sanofi reported FY2024 revenue of $44.8 billion ($44.6 billion USD at average 2024 exchange rate of 1.085), an increase of 8.6% reported and 11.3% at constant exchange rates (CER) compared to FY2023's $41.2 billion. This growth was driven by Dupixent's 23.1% increase to $14.3 billion, new product launches contributing 11% of total sales, and Beyfortus achieving blockbuster status at $1.9 billion in its first full year. Gross profit reached $33.9 billion ($33.7 billion), yielding a gross margin of 75.7%—among the highest in the pharmaceutical industry and reflecting the favorable mix shift toward biologics. Research and development expenses increased 14.6% to $8.1 billion ($8.0 billion), representing 18.0% of revenue, as Sanofi accelerated investment in pipeline assets including tolebrutinib, amitelimab, and the expanding Dupixent indication program. Selling, general, and administrative expenses totaled $10.0 billion ($10.0 billion), or 22.4% of revenue, with disciplined cost management keeping SG&A growth below sales growth. Business operating income was $12.3 billion ($12.3 billion), producing a business operating margin of 27.6%, though this declined 1.0 percentage point from 2023 due to the gross margin impact of product mix and higher R&D investment. Business net income reached $9.7 billion, with business earnings per share of $7.8, up 4.1% at CER and exceeding guidance. IFRS net income was $6.2 billion ($6.2 billion), with IFRS EPS of $5, up 6.5% reported. The difference between business and IFRS results reflects amortization of intangible assets ($1.9 billion), restructuring costs ($1.5 billion), and other non-recurring items. Free cash flow was $6.5 billion ($6.5 billion), down 19.6% from 2023 due to increased working capital requirements and capital expenditures. The Board of Directors proposed a dividend of $4.3 per share for 2024, marking the 30th consecutive year of dividend increases and representing a payout ratio of approximately 55% of business net income. Sanofi intends to execute a $5.5 billion ($5.4 billion) share buyback program in 2025, with shares purchased for cancellation. The balance sheet remains strong, with Scope Ratings affirming an AA issuer rating and Positive Outlook, reflecting Sanofi's robust cash generation and conservative leverage. Net debt is estimated at approximately $16.4 billion ($16.3 billion), representing a net debt-to-EBITDA ratio of approximately 1.1x and interest coverage exceeding 14x. The company's capital allocation prioritizes R&D investment (targeting 18-20% of revenue), business development including the $9.5 billion Blueprint Medicines acquisition and $1.5 billion Vicebio acquisition in 2025, shareholder returns through dividends and buybacks, and manufacturing capacity expansion including the $1.4 billion French biologics investment. Q1 2025 revenue was $10.8 billion ($10.5 billion at Q1 exchange rates), up 10.8% year-over-year, with Dupixent growing 20.0% to $3.8 billion and business operating income increasing 20.1% to $3.2 billion. Full-year 2025 guidance anticipates high single-digit sales growth at CER and low double-digit business EPS growth before share buyback impact.